Published in final edited form as:
Chem Biol. 2005 December ; 12(12): 1311–1315.

Chemo-enzymatic synthesis of glycopeptides using PglB, a bacterial oligosaccharyl transferase from *Campylobacter jejuni*

Kerney Jebrell Glover[1,3], **Eranthie Weerapana**[1,3], **Shin Numao**[2], and **Barbara Imperiali**[1,*]

[1]*Departments of Chemistry and Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA.* [2]*Institute of Microbiology, Department of Biology, Swiss Federal Institute of Technology (ETH), CH-8092, Zürich, Switzerland*

Summary

The gram-negative bacterium *Campylobacter jejuni* has a general *N*-linked glycosylation pathway encoded by the *pgl* gene cluster. One of the proteins in this cluster, PglB, is thought to be the oligosaccharyl transferase due to its significant homology to Stt3p, a subunit of the yeast oligosaccharyl transferase complex. PglB has been shown to be involved in catalyzing the transfer of an undecaprenyl-linked heptasaccharide to the asparagine side chain of proteins at the Asn-X-Ser/Thr motif. Using a synthetic disaccharide glycan donor (GalNAc-α1,3-bacillosamine-pyrophosphate-undecaprenyl) and a peptide acceptor substrate (KDFNVSKA), we can observe the oligosaccharyl transferase activity of PglB *in vitro*. Furthermore, the preparation of additional undecaprenyl-linked glycan variants reveals the ability of PglB to transfer a wide variety of saccharides. With the demonstration of PglB activity *in vitro*, fundamental questions surrounding the mechanism of *N*-linked glycosylation can now be addressed.

Introduction

Recent studies have revealed the presence of *N*-linked glycoproteins in the gram-negative bacterium *Campylobacter jejuni*, which is involved in human gastroenteric disorders [1]. Evidence suggests that these *N*-linked glycans play a major role in host adherence, invasion, and colonization [2]. Similar to the corresponding process in eukaryotes, the glycan is attached to the asparagine side chain at the Asn-X-Ser/Thr motif where X can be any amino acid except proline [3]. In *C. jejuni*, the glycan that is transferred is the heptasaccharide GalNAc-α1,4-GalNAc-α1,4-(Glcβ1,3)-GalNAc-α1,4-GalNAc-α1,4-GalNAc-α1,3-Bac, where Bac is bacillosamine (2,4-diacetamido-2,4,6-trideoxyglucose) [4]. Genetic studies have identified a locus (dubbed "*pgl*" for protein glycosylation) that is responsible for this process. This locus can be functionally reconstituted in *E. coli*, strongly suggesting that it contains all the genes necessary for the *N*-linked glycosylation process [5]. Three major classes of proteins are represented in the *pgl* gene cluster; carbohydrate-modifying enzymes responsible for the biosynthesis of the bacillosamine, glycosyltransferases that assemble the lipid-linked heptasaccharide, and most importantly the oligosaccharyl transferase (PglB), which is responsible for transferring the pre-assembled heptasaccharide to protein [6].

The current model for the *pgl* pathway (Figure 1) is based on bioinformatic, biochemical, and mutational analyses, and shares some features with the dolichol pathway in yeast and the O-antigen pathway in bacteria [6,7]. The pathway begins on the cytoplasmic side of the

*To whom correspondence may be addressed: imper@mit.edu.
[3]These authors contributed equally to this work.

periplasmic membrane with a UDP-HexNAc (either GlcNAc or GalNAc), which is converted to UDP-Bac. UDP-Bac is then linked to undecaprenyl phosphate through the action of PglC to create the first membrane-anchored intermediate undecaprenylpyrophosphate-linked bacillosamine (Und-PP-Bac). This product is then elaborated by PglA, J, H and I to produce the heptasaccharide, which is then flipped by WlaB into the periplasm. Once in the periplasm, PglB transfers the completed heptasaccharide affording a β-linked glycan to the asparagine side chain of target proteins.

PglB is an 83 kDa integral membrane protein that resides in the periplasmic membrane. It comprises two domains, a hydrophobic domain containing approximately 12 membrane-spanning segments and a smaller soluble domain (TMHMM, ExPASY). Interestingly PglB shares significant homology to Stt3p, a subunit of the nine member yeast oligosaccharyl transferase (OT) complex. Importantly, PglB and Stt3p along with other similar homologs have a conserved signature sequence of WWDYGY, which has been shown to be essential for activity *in vivo* [5].

In this study we have prepared a membrane fraction from *E. coli* in which PglB has been over-expressed. Using a synthetic undecaprenyl-linked glycan (GalNAc-α1,3-bacillosamine-pyrophosphate-undecaprenyl, GalNAc-Bac-PP-Und) [8] we have been able to observe the transfer of the disaccharide to the peptide acceptor (KDFNVSK). Further studies have revealed that PglB also accepts the disaccharides GalNAc-GlcNAc-PP-Und and GalNAc-6-hydroxybacillosamine-PP-Und. Studies also reveal that an octapeptide based upon sequences from known glycoproteins in *C. jejuni*, is favored over a simple N- and C-terminal capped NLT tripeptide revealing that there are additional amino acid determinants that provide optimal OT activity in the *C. jejuni* enzyme.

Results and Discussion

Substrates for *N*-linked glycosylation *in vitro*

In order to define the optimal peptide substrate, sequence alignments were done against two known periplasmic proteins, PEB3 and AcrA, which have been established to be glycosylated in *C. jejuni*. AcrA is glycosylated at Asn123, while PEB3 is glycosylated at Asn90 [9,10]. When those regions are aligned, the first three amino acids preceding the Asn are strictly conserved. However the residue after the Asn appears to be variable. The next two residues, Ser and Lys are also highly conserved in these two proteins. In order to create the consensus sequence for glycosylation, all conserved residues were retained to create the KDFNVSKA octapeptide sequence, which was prepared with a free N-terminus and a C-terminal amide (Figure 2A).

The lipid-linked sugar substrate was obtained chemo-enzymatically, using the glycosyltransferase PglA, which adds a GalNAc to Und-PP-Bac in high yield (also accepts Und-PP-GlcNAc and Und-PP-6-hydroxybacillosamine to a lesser extent). Und-PP-Bac is obtained via chemical synthesis [8] and radiolabeled disaccharide substrate can be readily prepared by using UDP-^{3}H-GalNAc as the substrate for the PglA reaction (Figure 2B). The disaccharide was selected as the minimal glycan donor for PglB based upon precedent from the eukaryotic oligosaccharyl transferases which readily accepts a truncated disaccharide substrate *in vitro* [11,12]. If the PglB reaction proceeds as anticipated, a glycosylated peptide containing the tritiated disaccharide will be formed (Figure 2C).

Preparation of PglB

Two PglB constructs were prepared. The native 83 kD PglB protein was cloned into a vector such that the final construct was a T7·Tag-PglB-$(His)_6$ (T7·Tag is for antibody recognition). In addition, since the bacterial, fungal and yeast OTs all contain a highly conserved, 6-residue

signature sequence WWDYGY (Figure 3A) a second homologous construct, in which two of these residues were mutated, was also prepared. According to the work of Aebi and co-workers, if the WWDYGY signature sequence is mutated to WAAYGY, PglB is no longer active *in vivo* [5]. Both proteins were over-expressed in *E. coli* and a bacterial membrane preparation of each was used for activity assays. The anti-T7 Western blot shown in Figure 3B confirms that both the wild type and mutant are expressed in *E. coli.* Next, both the mutant and wild type PglB were assayed for oligosaccharyl transferase activity. The assay used was one that was already established for assaying yeast microsomes for OT activity [11, 13]. Briefly, PglB is added to a solution containing the peptide and glycan substrates for PglB. An aqueous/organic phase separation partitions the peptide into the aqueous phase, while the tritiated polyprenol-linked saccharide starting material remains in the organic phase. If oligosaccharyl transferase activity is observed there will be a net transfer of radioactivity from the organic phase into the aqueous phase. The results from this assay are shown in Figure 3C. This assay clearly shows that the wild type PglB readily transfers radioactive carbohydrate to an aqueous soluble fraction whereas the mutant shows no comparable activity. Furthermore, the flat slope of the mutant curve confirms that there is negligible hydrolysis of the Und-PP-Bac pyrophosphate within the timeframe of the experiment.

In order to further confirm the presence of glycopeptide, the peptide products of overnight reactions were subjected to HPLC analysis. With wild-type PglB, the peptide product elutes from the reverse-phase column at T_R = 17.5 minutes (Figure 4A) while the peptide product from a similar incubation using the mutant PglB elutes at T_R = 18.0 minutes (Figure 4D). When these peaks are collected and subjected to mass spectral analysis, a mass corresponding to the glycopeptide is observed for the wild type (Figure 4B) while the mutant is that of the unglycosylated peptide (Figure 4E). The presence of a single peak in both mass spectra show that the glycopeptide product is not modified by host transferases or proteases. Interestingly, the presence of only a single product in the mass spectrum coupled with the appearance of a single HPLC peak suggests that there is complete conversion to glycopeptide. Furthermore if radiolabeled glycan substrate is used, a strong radioactive peak at a similar retention time as the glycopeptide (Figure 4C), confirms that the radioactivity in the aqueous layer is a result of radiolabeled glycopeptide and not a hydrolysis product, which elutes very early (T_R = 4 minutes) from the reverse-phase column (Figure 4C arrow). In addition, the assay including the mutant PglB, does not show a a strong radioactive peak (Figure 4F) further confirming that it is deficient in transferase activity.

Utilization of diverse Polyprenolpyrophosphate-linked glycans by PglB

Three disaccharide substrates were prepared using a chemo-enzymatic approach. As presented previously, synthetic Und-PP-bacillosamine, Und-PP-6-hydroxybacillosamine and Und-PP-GlcNAc were reacted with PglA and UDP-GalNAc to form the corresponding radiolabeled disaccharides [14]. These polyisoprene-linked disaccharides were then assayed with PglB to determine the specificity of PglB for the saccharide proximal to the pyrophosphate moiety. The results from this assay are shown in Figure 5. It appears that PglB will accept the unnatural 6-hydroxybacillosamine and GlcNAc analogs, although the bacillosamine substrate appears to be the most efficient of the three. These data agree with *in vivo* studies which have shown that PglB can transfer several structurally different O-antigen saccharides to protein [15].

The native substrate for PglB is a heptasaccharide, but we have shown that PglB readily accepts a disaccharide *in vitro*. Mutagenesis studies of proteins in the Pgl pathway have resulted in the transfer of truncated saccharides to protein, strongly suggesting that PglB has low specificity for the substrate length when functionally reconstituted in *E. coli* [10]. *In vitro* we can access truncated substrates using various combinations of glycosyltransferases in the *pgl* pathway. With PglA we can access the disaccharide (GalNAc-Bac), with PglA and J, we form the

trisaccharide ($GalNAc_2$-Bac), with PglA, J and H, we form hexasaccharide ($GalNAc_5$-Bac) and finally, with PglA, J, H and I we form the heptasaccharide ($GalNAc_2(Glc)GalNAc_3$-Bac) [14]. Studies with these intermediate sugars *in vitro*, demonstrate that PglB readily accepts these substrates (Figure 6), further reinforcing the observations made by Linton *et al*.[10] in the *in vivo* system.

Peptide specificity of PglB

Next, the oligosaccharyl transferase activity of PglB on the octapeptide was compared with the known tripeptide acceptor (Bz-NLT-NHMe) for the yeast OT system [12,13]. Clearly, Bz-NLT-NHMe is a poor acceptor for the bacterial system (Figure 7A). The Bz-NLT peptide was subjected to HPLC analysis similar to the consensus peptide discussed above. The HPLC trace (Figure 7B) shows the presence of 2 peaks which were confirmed by mass spectral analysis to be the glycopeptide (T_R = 27.0 min, Figure 7C) and its unglycosylated counterpart (T_R = 29.0 min, data not shown). The presence of a significant amount of unglycosylated peptide when subjected to the exact reaction conditions as the consensus peptide together with the low rate of transfer observed in Figure 7A strongly suggests that PglB has additional determinants for the peptide substrate beyond the minimal tripeptide consensus sequence that is well recognized in eukaryotes [3]. Further studies into the peptide specificity of PglB are currently in progress.

Significance

The experiments described here afford the first *in vitro* observation of oligosaccharyl transferase activity of PglB. By using a combination of chemical synthesis and enzymology we were able to prepare various glycan and peptide substrates for this remarkable enzyme. The results demonstrate that PglB has a relaxed substrate specificity accepting peptide substrates in place of full-length proteins, making it potentially useful for the preparation of artificial glycopeptides. Furthermore, the observation that PglB can transfer undecaprenyl-pyrophosphate-linked saccharides of various lengths (2−7 saccharides) adds to the promise of using PglB in the synthesis of diverse glycopeptide products. However, PglB does require determinants in the peptide sequence beyond the canonical N-X-S/T tripeptide and with this *in vitro* assay in place, further studies to determine the role of the amino acid binding determinants can be readily undertaken. Although the experiments described in this work strongly suggest that PglB is solely responsible for oligosaccharyl transferase activity, the presence of an accessory protein(s) in *E. coli* cannot be ruled out due to the use of a bacterial membrane fraction. Currently, work is underway to purify PglB to homogeneity, which will unambiguously demonstrate whether it alone is responsible for the oligosaccharyl transferase activity. Furthermore, detailed investigations into the poorly understood mechanism of oligosaccharyl transferases are more feasible using PglB as opposed to the multi-subunit eukaryotic complexes. Lastly, the development of powerful inhibitors of this enzyme would be valuable in the quest for antibiotics for *C. jejuni*-induced gastrointestinal disorders.

Experimental Procedures

Expression of PglB

Starting from a 5 mL overnight culture, *E. coli* strains expressing PglB were grown at 37°C in LB broth to an OD_{600} of 0.6−0.8. At that point, the temperature was reduced to 16°C and protein production was induced by the addition of IPTG (1 mM). After 24 hours, the cells were harvested by centrifugation (5000 × *g*) for 30 minutes, washed once with 0.9% NaCl solution, recentrifuged (5000 × g) for 30 minutes and frozen at −80°C until needed.

Preparation of PglB membrane fraction

All steps were performed at 4°C. The *E.coli* cell pellets expressing PglB (wild type and mutant) were thawed and resuspended in 5% of the original culture volume in buffer M (50 mM Tris-acetate [pH 8.0], 1 mM EDTA). The cells were then subjected to sonication (3 × 15 s), unbroken cells were removed by centrifugation at 5,697 × *g* for 15 minutes, and the membrane fraction was collected by centrifugation at 142,414 × *g* for 60 minutes. The pellet was washed once with buffer M, centrifuged again, and resuspended in 0.25% of the original culture volume in buffer M. The final suspension was aliquoted and stored at −80°C.

Preparation of lipid-linked disaccharides using PglA

To a tube containing 0.06 mg of dried Und-PP-Bac, Und-PP-6-hydroxybacillosamine or Und-PP-GlcNAc, 3 μL of DMSO, and 7 μL of 14.3% (v/v) Triton X-100 were added. After vortexing and sonication (water bath), 58 μL of H_2O, 4 μL of 1 M Tris-Acetate pH 8.5, 1 μL 1 M $MgCl_2$, and 20 μL PglA (660 μg/mL) were added. The reaction was initiated by the addition of 7.5 μL of UDP-GalNAc (55 nCi/nmol). After 120 minutes, the reaction was quenched in 1.6 mL of 2:1 chloroform:methanol and extracted three times with 320 μL of pure solvent upper phase (15 mL chloroform: 240 mL methanol: 235 mL water: 1.83 g KCl). The organic layer was aliquoted and dried under a stream of nitrogen (~20,000−30,000 DPM/tube).

Peptide Synthesis

Peptides were synthesized by automated peptide synthesis (Applied Biosystems ABI 431A peptide synthesizer) using standard Fmoc peptide synthesis conditions on PALPEG-PS resin. The resulting peptides were cleaved from the resin using trifluoroacetic acid and purified by preparative reverse phase high-pressure liquid chromatography using a standard acetonitrile/water gradient.

PglB Assay

To a tube of the labeled disaccharide, 10 μL DMSO, 100 μL of 2× assay Buffer (100mM HEPES, pH 7.5, 280 mM sucrose, 2.4% v/v Triton-X100), 2 μL of 1M $MnCl_2$ and 28 μL of water was added. Reactions were initiated by the addition of 10 μL of a 2 mM stock of the peptide in DMSO. 40 μL of the reaction mixture was removed at various time points and quenched into 1 mL of 3:2 chloroform: methanol + 200 μL of 4 mM $MgCl_2$. The aqueous layer was extracted and the organic layer was washed twice with 600 μL of pure solvent upper phase. The aqueous layers were combined, mixed with 5 mL of scintillation fluid (EcoLite, MP Biomedicals) and subjected to scintillation counting (2 minutes per tube).

HPLC analysis of glycopeptides

A 40 μL reaction aliquot was quenched as above and the aqueous layer was dried under vacuum. The residue was resuspended in 50 μL of water and injected on a reverse-phase C18 column and eluted under a standard water/acetonitrile gradient. Fractions were collected every minute, mixed with scintillation fluid (EcoLite, MP Biomedicals) and subjected to scintillation counting (2 minutes per tube).

Acknowledgements

This work was supported in full by the NIH: GM039334-19 to B.I. and postdoctoral fellowship (GM65699-03) to K. J. G.

References

1. Szymanski CM, Logan SM, Linton D, Wren BW. Campylobacter--a tale of two protein glycosylation systems. Trends Microbiol 2003;11:233–238. [PubMed: 12781527]

2. Szymanski CM, Burr DH, Guerry P. Campylobacter protein glycosylation affects host cell interactions. Infect Immun 2002;70:2242–2244. [PubMed: 11895996]

3. Nita-Lazar M, Wacker M, Schegg B, Amber S, Aebi M. The NX-S/T consensus sequence is required but not sufficient for bacterial N-linked protein glycosylation. Glycobiology 2005;15:361–367. [PubMed: 15574802]

4. Young NM, Brisson JR, Kelly J, Watson DC, Tessier L, Lanthier PH, Jarrell HC, Cadotte N, St Michael F, Aberg E, Szymanski CM. Structure of the N-linked glycan present on multiple glycoproteins in the Gram-negative bacterium, Campylobacter jejuni. J Biol Chem 2002;277:42530–42539. [PubMed: 12186869]

5. Wacker M, Linton D, Hitchen PG, Nita-Lazar M, Haslam SM, North SJ, Panico M, Morris HR, Dell A, Wren BW, Aebi M. N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science 2002;298:1790–1793. [PubMed: 12459590]

6. Szymanski CM, Wren BW. Protein glycosylation in bacterial mucosal pathogens. Nat Rev Microbiol 2005;3:225–237. [PubMed: 15738950]

7. Samuel G, Reeves P. Biosynthesis of O-antigens: genes and pathways involved in nucleotide sugar precursor synthesis and O-antigen assembly. Carbohydr Res 2003;338:2503–2519. [PubMed: 14670712]

8. Weerapana E, Glover KJ, Chen MM, Imperiali B. Investigating bacterial N-linked glycosylation: synthesis and glycosyl acceptor activity of the undecaprenylpyrophosphate-linked bacillosamine. J. Am. Chem. Soc. 2005In press

9. Linton D, Allan E, Karlyshev AV, Cronshaw AD, Wren BW. Identification of N-acetylgalactosamine-containing glycoproteins PEB3 and CgpA in Campylobacter jejuni. Mol Microbiol 2002;43:497–508. [PubMed: 11985725]

10. Linton D, Dorrell N, Hitchen PG, Amber S, Karlyshev AV, Morris HR, Dell A, Valvano MA, Aebi M, Wren BW. Functional analysis of the Campylobacter jejuni N-linked protein glycosylation pathway. Mol Microbiol 2005;55:1695–1703. [PubMed: 15752194]

11. Sharma CB, Lehle L, Tanner W. N-Glycosylation of yeast proteins. Characterization of the solubilized oligosaccharyl transferase. Eur J Biochem 1981;116:101–108. [PubMed: 7018901]

12. Imperiali B, Hendrickson TL. Asparagine-linked glycosylation: specificity and function of oligosaccharyl transferase. Bioorg Med Chem 1995;3:1565–1578. [PubMed: 8770382]

13. Imperiali B, Shannon KL. Differences between Asn-Xaa-Thr-containing peptides: a comparison of solution conformation and substrate behavior with oligosaccharyltransferase. Biochemistry 1991;30:4374–4380. [PubMed: 2021629]

14. Glover K,J, Weerapana E, Imperiali B. Insight into prokaryotic *N*-linked glycosylation: *in vitro* assembly of an undecaprenylpyrophosphate-linked heptasaccharide. Proc Natl Acad Sci U S A. 2005In press

15. Feldman MF, Wacker M, Hernandez M, Hitchen PG, Marolda CL, Kowarik M, Morris HR, Dell A, Valvano MA, Aebi M. Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. Proc Natl Acad Sci U S A 2005;102:3016–3021. [PubMed: 15703289]



Figure 1.
Schematic representation of the *C. jejuni pgl N*-glycosylation process



Figure 2. Design of peptide substrates and overview of PglA and PglB reactions

(A) Sequence alignment of residues flanking the glycosylation sites of PEB3 andAcrA and resulting consensus peptide.

(B) Synthesis of radiolabeled undecaprenyl-linked disaccharide using PglA, synthetic undecaprenyl-pyrophosphate bacillosamine, and tritiated UDP-GalNAc. Bold highlights position of the tritium label.

(C) Overview of desired PglB reaction using lipid-linked saccharide highlighted in (B) and the consensus peptide shown in (A).



Figure 3. ***In vitro*** **activity of wild type and mutant PglB**

(A) Sequence alignment of the highly conserved OT hexa-amino acid motif. The PglB mutant has two alanine substitutions within this motif.

(B) Anti-T7 Tag Western blot of bacterial membranes overexpressing PglB and the mutant counterpart. Lane 1, Wild type ; Lane 2, Mutant

(C) Plot of glycopeptide product formation as a function of time. Solid line, Wild type; Dashed line, Mutant. This plot is a representation of product formation and should not be interpreted as kinetic data.



Figure 4. Reverse-phase HPLC traces of peptide and glycopeptide products. (These experiments were performed with the more synthetically accessible 6-hydroxybacillosamine derivative)

(A) HPLC trace of peptide after PglB wild type reaction.
(B) MALDI-MS of glycopeptide product
(C) Radioactive HPLC trace of wild type PglB reaction.
(D) HPLC trace of peptide after PglB mutant reaction.
(E) MALDI-MS of unglycosylated peptide product.
(F) Radioactive HPLC trace of mutant PglB reaction.



Figure 5.

Specificity of PglB for undecaprenyl-pyrophosphate linked disaccharides. (^{3}H-GalNAc-X-PP-Und). Solid line, X= bacillosamine; Dashed line, X= GlcNAc; Dotted line, X= 6-hydroxybacillosamine. This plot is a representation of product formation, it is not a representation of kinetic analysis, and strong conclusions about acceptance rates should not be made.



Figure 6. Utilization of various undecaprenyl-pyrophosphate linked saccharide intermediates. The more readily available 6-hydroxybacillosamine substrate was used for this study in place of the native bacillosamine. The variation in the levels of DPM incorporation reflects the different amounts of lipid-linked sugar substrate in each reaction; Therefore conclusions about the relative reaction rates cannot be made

(A) ^{3}H-GalNAc-Bac-PP-Und.

(B) GalNAc-^{3}H-GalNAc-Bac-PP-Und.

(C) $(GalNAc)_4$-^{3}H-GalNAc-Bac-PP-Und.

(D) (Glc)-$(GalNAc)_4$-^{3}H-GalNAc-Bac-PP-Und.



Figure 7. Peptide substrate specificity of PglB

(A) Radioactive Assay of product formation. Solid line, octapeptide consensus sequence (KDFNVSKA); Dashed line, tripeptide consensus for yeast OT (Bz-NLT-NHMe). 6-hydroxybacillosamine was used in this study in place of the native bacillosamine substrate. Plot is not a representation of kinetic parameters. (B) HPLC trace of Bz-NLT-NHMe reaction. (C) MALDI-MS of Bz-NLT-NHMe glycopeptide (peak at T_R = 27.0 min).